Novel 11-substituted ellipticines as potent anticancer agents with divergent activity against cancer cells

Loading...
Thumbnail Image
Files
pharmaceuticals-12-00090.pdf(2.06 MB)
Published version
pharmaceuticals-12-00090-s001.pdf(4.45 MB)
Supplementary file 1
Date
2019-06-14
Authors
Miller, Charlotte M.
O'Sullivan, Elaine C.
McCarthy, Florence O.
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI AG
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
Ellipticines have well documented anticancer activity, in particular with substitution at the 1-, 2-, 6- and 9-positions. However, due to limitations in synthesis and coherent screening methodology the full SAR profile of this anticancer class has not yet been achieved. In order to address this shortfall, we have set out to explore the anticancer activity of this potent natural product by substitution. We currently describe the synthesis of novel 11-substituted ellipticines with two specific derivatives showing potency and diverging cellular growth effects.
Description
Keywords
Ellipticine , Anticancer , Heterocycli chemistry , Indole , NCI screen , Topoisomerase II
Citation
Miller, C. M., O’Sullivan, E. C. and McCarthy, F. O. (2019) 'Novel 11-Substituted Ellipticines as Potent Anticancer Agents with Divergent Activity against Cancer Cells', Pharmaceuticals, 12(2), 90 (15pp). DOI: 10.3390/ph12020090
Link to publisher’s version